TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD)

CUSIP: 88338N206

Q3 2023 13F Holders as of 30 Sep 2023

Holder snapshot 7 signals
Share change
-43,519
Put/Call ratio
36%
SEC-reported price per share
$3.02
Indexed holders
36
Value change
+$112,168
Number of buys
10
Open additional details 1 more signal available
Number of sells
14
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
11,627,985

Security key

88338N206

Report period

Q3 2023

Indexed institutions

36

Top holders

10

Ownership snapshot

Top reported holders of TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
John C.k. Milligan IV
Disclosed value leader
John C.k. Milligan IV
Comparable rows
0/15
Latest evidence
30 Jun 2023
3/4/5 13F Highest disclosed value: $12,698,322 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

John C.k. Milligan IV has the largest disclosed position value at $12.7M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens John C.k. Milligan IV's linked filing trail.
Disclosed position value Top 5
John C.k. Milligan IV $12.7M
Hugh O'Dowd $11.42M
Robert G. Finizio $5.31M
Rubric Capital Management LP $4.91M
Clearline Capital LP $1.88M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
John C.k. Milligan IV
3/4/5
Secretary/CEO of subsidiary
—
mixed-class rows
$12,698,322
5,542,076 shares
mixed-class rows
— 10 May 2021
Hugh O'Dowd
3/4/5
Chief Executive Officer
—
mixed-class rows
$11,415,713
4,250,000 shares
mixed-class rows
— 31 Mar 2022
Robert G. Finizio
3/4/5
CEO, Director
—
mixed-class rows
$5,305,888
2,240,000 shares
mixed-class rows
— 01 Jul 2021
Rubric Capital Management LP
13F
Company
13F
—
denominator unverified
$4,911,827
1,192,191 shares
— 30 Jun 2023
Clearline Capital LP
13F
Company
13F
—
denominator unverified
$1,876,133
455,372 shares
— 30 Jun 2023
James Darecca
3/4/5
Chief Financial Officer
—
mixed-class rows
$1,857,402
558,163 shares
mixed-class rows
— 10 Aug 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
36
Shares
2,987,555
Indexed holders
36
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 indexed holders
40
Q3 2023 indexed holders
36
Indexed holder difference
-4
Investor Q2 2023 Shares Q3 2023 Shares Share Diff Share Chg % Q2 2023 value Q3 2023 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .